Department of Bioengineering and Therapeutic Sciences

School introduces new Master of Science program in Artificial Intelligence and Computational Drug Discovery and Development

The first program of its kind in the United States, the MS in AICD3 will enable its graduates to gain a competitive edge for some of the most desirable jobs in the biopharmaceutical industry and in academia.

Holly Ly, PharmD

CERSI Education Coordinator

I serve as Education Coordinator for the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI), a research collaboration between UCSF, Stanford University, and the U.S. Food and Drug Administration (FDA).

Guo named inaugural director of new Center for Collaborative Innovation

Su Guo, PhD, will lead a new center to increase collaboration between clinical, translational, and discovery science in teaching and research.

PharmD program creates new opportunities to explore industry and research career paths

Students keep pace with latest innovations through experiential options and advanced degrees.

Joanne Chun, PharmD, PhD

Director, MS in AICD3


As director of post­graduate education programs, I spearhead the creation and de­vel­op­ment of new edu­ca­tion­al programs, enhancing our educational initiatives and creating unparalleled op­por­tun­i­ties for graduates in the field of drug discovery and de­vel­op­ment. My passion is anchored in...

Kortemme named new vice dean of research

Computational biology and protein engineering expert will focus on cultivating collaboration.

QBI and Director Krogan’s COVID and infectious disease efforts continue to make waves

QBI publishes breakthrough on COVID-19 variants; Nevan Krogan recognized as trailblazer.

Update from the Dean: Putting plans in action

Dean Kathy Giacomini shares how the School’s recent breakthroughs and accomplishments are bringing our new strategic plan to life.

The Kidney Project proves its bioreactor can keep kidney cells alive for at least one week

Scientists have shown for the first time that kidney cells—housed in an implantable device called a bioreactor—can survive while implanted.

A budding partnership with Korean regulatory science pharmacists

A delegation from South Korea visited to sign a Memorandum of Understand (MOU) initiating potential collaborations between UCSF and Korean schools of pharmacy.

Pages